Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Opdivo-Yervoy nivolumab-ipilimumab Malignant Pleural Mesothelioma (MPM) Reimburse with clinical criteria and/or conditions Complete
Rinvoq upadacitinib Psoriatic Arthritis, adults Reimburse with clinical criteria and/or conditions Complete
Venclexta venetoclax Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Venclexta venetoclax Acute myeloid leukemia Do not reimburse Complete
Entuzity KwikPen human insulin Diabetes mellitus Reimburse with clinical criteria and/or conditions Complete
Jorveza budesonide Maintenance of Eosinophilic esophagitis in adults Reimburse with clinical criteria and/or conditions Complete
Vyxeos daunorubicin and cytarabine Acute myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Tecartus brexucabtagene autoleucel Mantle cell lymphoma Reimburse with clinical criteria and/or conditions Complete
Evrysdi risdiplam Spinal muscular atrophy Reimburse with clinical criteria and/or conditions Complete
Saxenda liraglutide Chronic weight management in adults Do not reimburse Complete